Last updated on April 20, 2014 at 17:20 EDT

Latest PID Stories

2012-11-16 04:21:18

LUXEMBOURG and DONGYING, China, Nov. 16, 2012 /PRNewswire/--CNPV Solar Power SA, a public limited liability company organized under the laws of the Grand Duchy of Luxembourg and a leading integrated manufacturer of solar photovoltaic products, today confirmed their extended success within the Potential Induced Degradation (PID) certification evaluation IEC62804, sanctioning their PID free status for both Monocrystalline and Polycrystalline modules. (Logo:...

2012-10-03 22:20:41

FLORENCE, Italy, Oct. 4, 2012 /PRNewswire/ -- A new study conducted in Japan supports the previously demonstrated safety and efficacy of Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID). The data were presented today at the 15th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Hizentra is the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of PID, a rare and...